Ignite Creation Date:
2024-05-05 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00072969
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
2003-11-12
Brief Title:
A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody Daclizumab Versus Antithymocyte Globulin ATG to Treat the Cytopenia of Myelodysplastic Syndrome MDS
Sponsor:
National Heart Lung and Blood Institute NHLBI
Organization:
National Institutes of Health Clinical Center CC
Organization Data
Organization:
National Institutes of Health Clinical Center CC
Class:
NIH
Study ID:
040026
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
National Heart Lung and Blood Institute NHLBI
Lead Sponsor Class:
NIH
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None